reports
Park Hotels & Resorts Inc. Reports First Quarter 2024 Results
Park Hotels & Resorts Inc. Reports First Quarter 2024 Results TYSONS, Va., April 30, 2024 (GLOBE NEWSWIRE) -- Park Hotels & Resorts Inc. (“Park” or the “Company”) (NYSE: PK) today announced results for the first quarter ended March 31, 2024 and provided an operational update. Selected Statistical and Financial Information (unaudited, amounts in millions, except RevPAR, ADR, Total RevPAR and per share data) Three Months Ended March 31, 2024 2023 Change(1)Comparable RevPAR$175.65 $162.91 7.8%Comparable Occupancy 70.9% 67.4% 3.5% ptsComparable ADR$247.91 $241.96 2.5% Comparable...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
RGLD ROYAL GOLD INC
URI UNITED RENTALS INC.
DOV DOVER CORPORATION
MTH MERITAGE HOMES CORPORATION
MRK MERCK & CO. INC.
FORM FORMFACTOR INC.
CPF CENTRAL PACIFIC FINANCIAL CORP.
CHDN CHURCHILL DOWNS INCORPORATED
AR ANTERO RESOURCES CORPORATION
UVSP UNIVEST FINANCIAL CORPORATION
VIRT VIRTU FINANCIAL INC. CLASS A
NOC NORTHROP GRUMMAN CORPORATION
CECE CECO ENVIRONMENTAL CORP.
CMG CHIPOTLE MEXICAN GRILL INC.
PI IMPINJ INC.
MRUS MERUS B V
ADES ADVANCED EMISSIONS SOLUTIONS
HCC WARRIOR MET COAL INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
KDP KEURIG DR PEPPER INC.
MMMB MAMAMANCINI'S HOLDINGS INC
FXI ISHARES CHINA LARGE-CAP ETF
STRA STRATEGIC EDUCATION INC.
DELL DELL TECHNOLOGIES INC CLASS C
TNK TEEKAY TANKERS
AIMD.P AIM4 VENTURES
ALXO ALX ONCOLOGY HOLDINGS
CSU CAPITAL SENIOR LIVING
LRN STRIDE INC
VRT VERTIV HOLDINGS CO (A)
AMR ALPHA METALLURGICAL RESOURCES INC
RSVR RESERVOIR MEDIA
CADL INC.
SG CANDEL THERAPEUTICS INC
EEMA SWEETGREEN INC
CASH ONTO INNOVATION INC.
FEBO ISHARES MSCI EMERGING MARKETS ASIA INDEX
METC HORIZONS HIGH INTEREST SAVINGS ETF
PROP FENBO HOLDINGS LIMITED
AESI RAMACO RESOURCES INC.
PRAIRIE OPERATING CO.
ATLAS ENERGY SOLUTIONS INC CL A
CORRECTING and REPLACING Expro Group Holdings N.V. Announces First Qua...
HOUSTON--(BUSINESS WIRE)-- Sixth paragraph, last sentence of the release should read: Second quarter revenue is expected to reflect approximately 3% year-on-year growth and sequential growth of 7%, with Adjusted EBITDA Margin in an expected range of 20% to 21%, or up 200 to 300 basis points year-on-year and sequentially in both cases based on the mid-point of second quarter guidance (instead of Second quarter revenue is expected to reflect approximately 20% year-on-year growth and sequential growth of 8%, with Adjusted EBITDA Margin in an expected range of 20% to 21%, or up 200 to 300 basis po...
- Wedbush Research
KMX CARMAX INC.
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
GPN GLOBAL PAYMENTS INC.
WDC WESTERN DIGITAL CORPORATION
V VISA INC. CLASS A
TRNO TERRENO REALTY CORPORATION
TPH TRI POINTE HOMES INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
REXR REXFORD INDUSTRIAL REALTY INC.
PSTG PURE STORAGE INC. CLASS A
PPBI PACIFIC PREMIER BANCORP INC.
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
MTH MERITAGE HOMES CORPORATION
KPTI KARYOPHARM THERAPEUTICS
INTC INTEL CORPORATION
GPC GENUINE PARTS COMPANY
GOOGL ALPHABET INC. CLASS A
FR FIRST INDUSTRIAL REALTY TRUST INC.
FITB FIFTH THIRD BANCORP
FISV FISERV INC.
FIS FIDELITY NATIONAL INFORMATION SERVICES INC.
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
EWBC EAST WEST BANCORP INC.
EGP EASTGROUP PROPERTIES INC.
CVBF CVB FINANCIAL CORP.
CTMX CYTOMX THERAPEUTICS INC.
CNK CINEMARK HOLDINGS INC.
CMRX CHIMERIX INC
CCS CENTURY COMMUNITIES INC.
BPMC BLUEPRINT MEDICINES CORP.
BIIB BIOGEN INC.
AZO AUTOZONE INC.
AAP ADVANCE AUTO PARTS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
CMG CHIPOTLE MEXICAN GRILL INC.
SLM SLM CORP
TSC TRISTATE CAPITAL HOLDINGS INC
ORLY O'REILLY AUTOMOTIVE INC.
CVNA CARVANA CO. CLASS A
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
SNBR SLEEP NUMBER CORPORATION
AMD ADVANCED MICRO DEVICES INC.
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
COOP MR. COOPER GROUP INC.
PINS PINTEREST INC. CLASS A
C TEST
SWTX SPRINGWORKS THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PFSI PENNYMAC FINANCIAL SERVICES INC.
RVMD REVOLUTION MEDICINES
BDTX BLACK DIAMOND THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ORIC ORIC PHARMACEUTICALS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
FUBO FUBOTV
COGT COGENT BIOSCIENCES INC
IMNM IMMUNOME
VOR VOR BIOPHARMA
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
FHTX FOGHORN THERAPEUTICS
STX SEAGATE TECHNOLOGY HLDGS PLC
IKNA IKENA ONCOLOGY INC
TCRX TSCAN THERAPEUTICS INC
ALIT FOLEY TRASIMENE ACQUISITION CORP
HOWL WEREWOLF THERAPEUTICS INC
GLUE MONTE ROSA THERAPEUTICS INC
CMPX COMPASS THERAPEUTICS
GMTX GEMINI THERAPEUTICS INC
JANX JANUX THERAPEUTICS INC
P PANDORA MEDIA
TYRA TYRA BIOSCIENCES INC
HR HEALTHCARE TRUST OF AMERICA INC.
NUVL NUVALENT INC
BOLD AUDENTES THERAPEUTICS
DBD DIEBOLD NIXDORF INC
NCR NCR NIGERIA
- David Carlson
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
KPTI KARYOPHARM THERAPEUTICS
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
TSC TRISTATE CAPITAL HOLDINGS INC
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
C TEST
SWTX SPRINGWORKS THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
BDTX BLACK DIAMOND THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ORIC ORIC PHARMACEUTICALS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
COGT COGENT BIOSCIENCES INC
IMNM IMMUNOME
VOR VOR BIOPHARMA
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
FHTX FOGHORN THERAPEUTICS
IKNA IKENA ONCOLOGY INC
TCRX TSCAN THERAPEUTICS INC
HOWL WEREWOLF THERAPEUTICS INC
GLUE MONTE ROSA THERAPEUTICS INC
CMPX COMPASS THERAPEUTICS
GMTX GEMINI THERAPEUTICS INC
JANX JANUX THERAPEUTICS INC
P PANDORA MEDIA
TYRA TYRA BIOSCIENCES INC
HR HEALTHCARE TRUST OF AMERICA INC.
NUVL NUVALENT INC
BOLD AUDENTES THERAPEUTICS
Merus gibt Annahme von Abstracts zur Präsentation auf der ASCO-Jahrest...
Merus gibt Annahme von Abstracts zur Präsentation auf der ASCO-Jahrestagung 2024 bekannt Petosemtamab in Kombination mit Pembrolizumab als 1L bei HNSCC – erste vorläufige klinische Daten für eine mündliche Kurzpräsentation ausgewählt MCLA-145 als Monotherapie oder in Kombination mit Pembrolizumab bei soliden Tumoren – erste vorläufige klinische Daten für eine mündliche Kurzpräsentation ausgewählt MCLA-129 bei NSCLC mit c-MET-Exon-14-Skipping-Mutationen – erste vorläufige klinische Daten für eine Posterpräsentation ausgewählt UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, April 25, 2...
Merus annonce les résumés acceptés pour présentation à la réunion annu...
Merus annonce les résumés acceptés pour présentation à la réunion annuelle 2024 de l’ASCO Pétosemtamab en association avec le pembrolizumab en traitement de première intention du carcinome épidermoïde de la tête et du cou : premières données cliniques provisoires sélectionnées pour une présentation orale rapide MCLA-145 en monothérapie ou en association avec le pembrolizumab dans les tumeurs solides : premières données cliniques provisoires sélectionnées pour une présentation orale rapide MCLA-129 dans le cancer bronchique non à petites cellules avec mutations conduisant à un saut de ...
Northrim BanCorp Earns $8.2 Million, or $1.48 Per Diluted Share, in Fi...
Northrim BanCorp Earns $8.2 Million, or $1.48 Per Diluted Share, in First Quarter 2024 ANCHORAGE, Alaska, April 24, 2024 (GLOBE NEWSWIRE) -- Northrim BanCorp, Inc. (NASDAQ:NRIM) (“Northrim” or the “Company”) today reported net income of $8.2 million, or $1.48 per diluted share, in the first quarter of 2024, compared to $6.6 million, or $1.19 per diluted share, in the fourth quarter of 2023, and $4.8 million, or $0.84 per diluted share, in the first quarter a year ago. The increase in first quarter 2024 profitability as compared to the prior quarter was primarily the result of an increase ...
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO A...
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation MCLA-145 as monotherapy or in combination with pembrolizumab in solid tumors initial interim clinical data selected for rapid oral session presentation MCLA-129 in NSCLC with c-MET exon 14 skipping mutations initial interim clinical data selected for poster presentation UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Me...
Park Hotels & Resorts Inc. Announces Second Quarter Dividend of $0.25 ...
Park Hotels & Resorts Inc. Announces Second Quarter Dividend of $0.25 Per Share TYSONS, Va., April 19, 2024 (GLOBE NEWSWIRE) -- Park Hotels & Resorts Inc. (NYSE: PK) (“Park” or the “Company”) announced today that the Company has declared a second quarter cash dividend of $0.25 per share of common stock. The dividend will be paid in cash on July 15, 2024 to stockholders of record as of June 28, 2024. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securiti...
- David Carlson
- David Nierengarten
- Dennis Pak
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
XENE XENON PHARMACEUTICALS INC
VRTX VERTEX PHARMACEUTICALS INCORPORATED
SRPT SAREPTA THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
SAGE SAGE THERAPEUTICS INC.
RGNX REGENXBIO INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PCRX PACIRA BIOSCIENCES INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MNKD MANNKIND CORP.
LL LUMBER LIQUIDATORS HOLDINGS INC.
KURA KURA ONCOLOGY INC.
HD HOME DEPOT INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
TSC TRISTATE CAPITAL HOLDINGS INC
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
NTLA INTELLIA THERAPEUTICS INC.
PK PARK HOTELS & RESORTS INC.
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
OVID OVID THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
VRNA VERONA PHARMA ADS
SE SEA ADS
AMD ADVANCED MICRO DEVICES INC.
APLS APELLIS PHARMACEUTICALS
UBX UNITY BIOTECHNOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
AX AXOS FINANCIAL INC.
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
IMUX IMMUNIC INC
GOSS GOSSAMER BIO
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
APRE APREA THERAPEUTICS
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
PASG PASSAGE BIO
ACET ADICET BIO INC
ASO ACADEMY SPORTS AND OUTDOORS
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
GBIO GENERATION BIO
PRAX PRAXIS PRECISION MEDICINES
COGT COGENT BIOSCIENCES INC
VOR VOR BIOPHARMA
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
OMGA OMEGA THERAPEUTICS
SBTX SILVERBACK THERAPEUTICS
TNGX TANGO THERAPEUTICS
LBPH INC
IKNA LONGBOARD PHARMACEUTICALS
TCRX IKENA ONCOLOGY INC
VERA TSCAN THERAPEUTICS INC
HOWL VERA THERAPEUTICS INC
GLUE WEREWOLF THERAPEUTICS INC
AVTE MONTE ROSA THERAPEUTICS INC
CMPX AEROVATE THERAPEUTICS INC
GMTX COMPASS THERAPEUTICS
JANX GEMINI THERAPEUTICS INC
VIGL JANUX THERAPEUTICS INC
MLTX VIGIL NEUROSCIENCE INC
TYRA MOONLAKE IMMUNOTHERAPEUTICS
PEPG TYRA BIOSCIENCES INC
HR PEPGEN INC
EWTX HEALTHCARE TRUST OF AMERICA INC.
PRME EDGEWISE THERAPEUTICS INC
OCS PRIME MEDICINE INC
APGE OCULIS HOLDING AG
DNTH APOGEE THERAPEUTICS INC
DIANTHUS THERAPEUTICS INC
Expro Group Holdings N.V. Schedules First Quarter 2024 Earnings Releas...
HOUSTON--(BUSINESS WIRE)-- Expro Group Holdings N.V. (NYSE: XPRO) (“Expro” or the “Company”) will hold a conference call on April 25, 2024 to discuss results for the quarter ended March 31, 2024. The conference call is scheduled to begin at 9:00 a.m. Central Time (10:00 a.m. Eastern Time). A press release regarding the results will be issued before the market opens on April 25 and the press release, together with associated presentation slides, will be posted to the investor relations section of the Expro website in advance of the conference call. We encourage those who plan to dial-in to th...
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Canc...
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024 UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced preclinical data on zenocutuzumab (Zeno) in cancer models with high neuregulin 1 (NRG1) expression were presented at the American Association of Cancer Research (AACR) Annual Me...
Merus stellt auf der AACR-Jahrestagung 2024 präklinische Daten als Bel...
Merus stellt auf der AACR-Jahrestagung 2024 präklinische Daten als Beleg für die Wirksamkeit von Zeno in Krebsmodellen mit hoher NRG1-Expression vor UTRECHT, Niederlande, und CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) („Merus“, „das Unternehmen“, „wir“ oder „unser“), ein in der klinischer Phase tätiges Unternehmen im Bereich der Onkologie, das innovative multispezifische Antikörper in voller Länge (Biclonics® und Triclonics®) entwickelt, gab heute die Vorstellung von präklinischen Daten zu Zenocutuzumab (Zeno) in Krebsmodellen mit hoher Neuregulin 1 (NRG1)-Expres...
Merus présente des données précliniques démontrant l’efficacité de Zen...
Merus présente des données précliniques démontrant l’efficacité de Zeno dans le traitement des modèles de cancer avec une forte expression du gène NRG1 lors de la réunion annuelle 2024 de l’AACR UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 08 avr. 2024 (GLOBE NEWSWIRE) -- (Nasdaq : MRUS) (« Merus », la « Société », « nous » ou « notre »)/« nos », une société spécialisée dans l’oncologie au stade clinique développant des anticorps de pleine longueur multispécifiques innovants (Biclonics® et Triclonics®), a annoncé aujourd’hui que des données précliniques sur le zénocutuzumab (« Zeno ») ...
Expro Report Highlights Progress Unlocking Energy Answers of Tomorrow
HOUSTON--(BUSINESS WIRE)-- Expro (NYSE: XPRO), a leading provider of energy services, has published its latest sustainability report, highlighting the Company’s achievements in 2023 along with the progress it has made during that time working toward its near- and long-term environmental, social and governance (ESG) objectives. This press release features multimedia. View the full release here: Headshot of Mike Jardon, Chief Executive Officer of Expro. (Photo: Business Wire) Projects delivered this year, that are highlighted in the report, include a custom solution to support the testing of ne...
Merus nimmt an einem Kamingespräch auf der 23. jährlichen Needham Virt...
Merus nimmt an einem Kamingespräch auf der 23. jährlichen Needham Virtual Healthcare Conference teil UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, April 03, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS), ein im klinischen Stadium tätiges Onkologieunternehmen, das innovative multispezifische Antikörper in voller Länge (Biclonics® und Triclonics®) entwickelt, hat heute bekanntgegeben, dass Dr. Bill Lundberg, President und Chief Executive Officer von Merus, am Mittwoch, 10. April 2024, um 8:45 Uhr (Eastern Time) an einem Kamingespräch auf der 23. jährlichen Needham Virtual Healthcare Confer...
Merus participera à une discussion informelle lors de la 23e conférenc...
Merus participera à une discussion informelle lors de la 23e conférence annuelle Needham Virtual Healthcare UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 03 avr. 2024 (GLOBE NEWSWIRE) -- (Nasdaq : MRUS), une société spécialisée dans l’oncologie au stade clinique développant des anticorps de pleine longueur multispécifiques et novateurs (Biclonics® et Triclonics®), annonce ce jour la participation de Bill Lundberg, M.D., Président et directeur général de Merus, à une discussion informelle lors de la 23e conférence annuelle Needham Virtual Healthcare qui se tiendra le mercredi 10 avril 20...
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Vir...
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 8:45 a.m. ET. The webcast of the presentation will be cont...
Douglas Emmett Announces Dates for Its 2024 First Quarter Earnings Res...
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Douglas Emmett, Inc. (NYSE:DEI), a real estate investment trust (REIT), announced today that it plans to release its 2024 first quarter earnings results after market close on Tuesday, May 7, 2024. A live conference call is scheduled for the following day, Wednesday, May 8, 2024, at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time. Jordan Kaplan, President and Chief Executive Officer, will host the call along with Peter Seymour, Chief Financial Officer; Kevin Crummy, Chief Investment Officer; and Stuart McElhinney, Vice President Investor Relations. Inter...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.